• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用纵向处方和医疗索赔数据进行机器学习,以检测非酒精性脂肪性肝炎(NASH)。

Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH).

机构信息

Real World Solutions, IQVIA, London, UK.

Real World Solutions, IQVIA, Plymouth Meeting, Pennsylvania, USA

出版信息

BMJ Health Care Inform. 2022 Mar;29(1). doi: 10.1136/bmjhci-2021-100510.

DOI:10.1136/bmjhci-2021-100510
PMID:35354641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8968511/
Abstract

OBJECTIVES

To develop and evaluate machine learning models to detect patients with suspected undiagnosed non-alcoholic steatohepatitis (NASH) for diagnostic screening and clinical management.

METHODS

In this retrospective observational non-interventional study using administrative medical claims data from 1 463 089 patients, gradient-boosted decision trees were trained to detect patients with likely NASH from an at-risk patient population with a history of obesity, type 2 diabetes mellitus, metabolic disorder or non-alcoholic fatty liver (NAFL). Models were trained to detect likely NASH in all at-risk patients or in the subset without a prior NAFL diagnosis (at-risk non-NAFL patients). Models were trained and validated using retrospective medical claims data and assessed using area under precision recall curves and receiver operating characteristic curves (AUPRCs and AUROCs).

RESULTS

The 6-month incidences of NASH in claims data were 1 per 1437 at-risk patients and 1 per 2127 at-risk non-NAFL patients . The model trained to detect NASH in all at-risk patients had an AUPRC of 0.0107 (95% CI 0.0104 to 0.0110) and an AUROC of 0.84. At 10% recall, model precision was 4.3%, which is 60× above NASH incidence. The model trained to detect NASH in the non-NAFL cohort had an AUPRC of 0.0030 (95% CI 0.0029 to 0.0031) and an AUROC of 0.78. At 10% recall, model precision was 1%, which is 20× above NASH incidence.

CONCLUSION

The low incidence of NASH in medical claims data corroborates the pattern of NASH underdiagnosis in clinical practice. Claims-based machine learning could facilitate the detection of patients with probable NASH for diagnostic testing and disease management.

摘要

目的

开发和评估机器学习模型,以检测疑似未确诊非酒精性脂肪性肝炎(NASH)的患者,用于诊断筛查和临床管理。

方法

在这项使用来自 1463089 名患者的行政医疗索赔数据的回顾性观察性非干预性研究中,使用梯度提升决策树来从有肥胖、2 型糖尿病、代谢紊乱或非酒精性脂肪肝(NAFL)病史的高危患者人群中检测可能患有 NASH 的患者。模型被训练用于检测所有高危患者或无先前 NAFL 诊断的亚组(高危非 NAFL 患者)中可能患有 NASH 的患者。使用回顾性医疗索赔数据对模型进行训练和验证,并使用精度-召回曲线下面积和接收器操作特征曲线(AUPRC 和 AUROC)进行评估。

结果

在索赔数据中,NASH 的 6 个月发生率为每 1437 名高危患者 1 例和每 2127 名高危非 NAFL 患者 1 例。训练用于检测所有高危患者 NASH 的模型的 AUPRC 为 0.0107(95%CI 0.0104 至 0.0110),AUROC 为 0.84。在 10%召回率下,模型精度为 4.3%,是 NASH 发病率的 60 倍。训练用于检测非 NAFL 队列中 NASH 的模型的 AUPRC 为 0.0030(95%CI 0.0029 至 0.0031),AUROC 为 0.78。在 10%召回率下,模型精度为 1%,是 NASH 发病率的 20 倍。

结论

医疗索赔数据中 NASH 的低发生率证实了 NASH 在临床实践中诊断不足的模式。基于索赔的机器学习可以帮助检测可能患有 NASH 的患者,以进行诊断测试和疾病管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeda/8968511/6d38f04989c6/bmjhci-2021-100510f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeda/8968511/123972b7b53a/bmjhci-2021-100510f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeda/8968511/348df43e0e36/bmjhci-2021-100510f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeda/8968511/220cddf937fc/bmjhci-2021-100510f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeda/8968511/6d38f04989c6/bmjhci-2021-100510f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeda/8968511/123972b7b53a/bmjhci-2021-100510f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeda/8968511/348df43e0e36/bmjhci-2021-100510f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeda/8968511/220cddf937fc/bmjhci-2021-100510f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeda/8968511/6d38f04989c6/bmjhci-2021-100510f04.jpg

相似文献

1
Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH).利用纵向处方和医疗索赔数据进行机器学习,以检测非酒精性脂肪性肝炎(NASH)。
BMJ Health Care Inform. 2022 Mar;29(1). doi: 10.1136/bmjhci-2021-100510.
2
Machine learning to predict progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis or fibrosis.机器学习预测非酒精性脂肪肝向非酒精性脂肪性肝炎或肝纤维化的进展
JGH Open. 2022 Mar 8;6(3):196-204. doi: 10.1002/jgh3.12716. eCollection 2022 Mar.
3
Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.基于组学和有监督学习的非酒精性脂肪性肝炎和肝纤维化的无创诊断:概念验证研究。
Metabolism. 2019 Dec;101:154005. doi: 10.1016/j.metabol.2019.154005. Epub 2019 Nov 9.
4
Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients.机器学习方法在非酒精性脂肪肝(NAFL)患者中预测非酒精性脂肪性肝炎(NASH)的应用。
AMIA Annu Symp Proc. 2018 Dec 5;2018:430-439. eCollection 2018.
5
Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis.开发一种新型机器学习模型以预测非酒精性脂肪性肝炎的存在。
J Am Med Inform Assoc. 2021 Jun 12;28(6):1235-1241. doi: 10.1093/jamia/ocab003.
6
Artificial Intelligence in Identifying Patients With Undiagnosed Nonalcoholic Steatohepatitis.人工智能在识别未诊断的非酒精性脂肪性肝炎患者中的应用
J Health Econ Outcomes Res. 2024 Sep 25;11(2):86-94. doi: 10.36469/001c.123645. eCollection 2024.
7
Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis.血清 C16:1n7/C16:0 比值作为非酒精性脂肪性肝炎的诊断标志物。
J Gastroenterol Hepatol. 2019 Oct;34(10):1829-1835. doi: 10.1111/jgh.14654. Epub 2019 Apr 7.
8
Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.血清铁蛋白与非酒精性脂肪性肝病的关系:一项荟萃分析。
Lipids Health Dis. 2017 Dec 2;16(1):228. doi: 10.1186/s12944-017-0613-4.
9
[Prevalence and clinical features of non-alcoholic steatohepatitis in a hypertensive population].[高血压人群中非酒精性脂肪性肝炎的患病率及临床特征]
Hipertens Riesgo Vasc. 2019 Jul-Sep;36(3):130-136. doi: 10.1016/j.hipert.2018.10.001. Epub 2019 Jan 14.
10
LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.LDL-迁移指数(LDL-MI),一种小而密低密度脂蛋白(sdLDL)的指标,在非酒精性脂肪性肝炎中高于非酒精性脂肪肝:一项多中心横断面研究。
PLoS One. 2014 Dec 26;9(12):e115403. doi: 10.1371/journal.pone.0115403. eCollection 2014.

引用本文的文献

1
Identifying and characterising asthma subgroups at high risk of severe exacerbations using machine learning and longitudinal real-world data.利用机器学习和纵向真实世界数据识别和表征重度加重高风险哮喘亚组。
BMJ Health Care Inform. 2025 Jul 7;32(1):e101282. doi: 10.1136/bmjhci-2024-101282.
2
Machine Learning-Based Non-Invasive Prediction of Metabolic Dysfunction-Associated Steatohepatitis in Obese Patients: A Retrospective Study.基于机器学习的肥胖患者代谢功能障碍相关脂肪性肝炎的无创预测:一项回顾性研究。
Diagnostics (Basel). 2025 Apr 25;15(9):1096. doi: 10.3390/diagnostics15091096.
3
Innovative approaches to metabolic dysfunction-associated steatohepatitis diagnosis and stratification.

本文引用的文献

1
Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis.开发一种新型机器学习模型以预测非酒精性脂肪性肝炎的存在。
J Am Med Inform Assoc. 2021 Jun 12;28(6):1235-1241. doi: 10.1093/jamia/ocab003.
2
Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail.用于非酒精性脂肪性肝炎(NASH)的药物:对圣杯的探寻。
J Clin Transl Hepatol. 2021 Feb 28;9(1):40-50. doi: 10.14218/JCTH.2020.00055. Epub 2020 Dec 9.
3
Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine.
代谢功能障碍相关脂肪性肝炎诊断与分层的创新方法
Noncoding RNA Res. 2024 Oct 11;10:206-222. doi: 10.1016/j.ncrna.2024.10.002. eCollection 2025 Feb.
4
Artificial Intelligence in Identifying Patients With Undiagnosed Nonalcoholic Steatohepatitis.人工智能在识别未诊断的非酒精性脂肪性肝炎患者中的应用
J Health Econ Outcomes Res. 2024 Sep 25;11(2):86-94. doi: 10.36469/001c.123645. eCollection 2024.
5
Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis.在美国,为治疗非肝硬化性 NASH 伴中重度肝纤维化的成年人,估算有资格使用雷美替胺的人群。
Adv Ther. 2024 Nov;41(11):4172-4190. doi: 10.1007/s12325-024-02989-5. Epub 2024 Sep 18.
6
The evolution and revolution of artificial intelligence in hepatology: From current applications to future paradigms.人工智能在肝病学中的演进与变革:从当前应用到未来模式
Hepatol Forum. 2024 Jul 2;5(3):97-99. doi: 10.14744/hf.2024.2024.ed0001. eCollection 2024.
7
Predicting Non-Alcoholic Steatohepatitis: A Lipidomics-Driven Machine Learning Approach.预测非酒精性脂肪性肝炎:一种基于脂质组学的机器学习方法。
Int J Mol Sci. 2024 May 29;25(11):5965. doi: 10.3390/ijms25115965.
8
Machine learning approaches for early detection of non-alcoholic steatohepatitis based on clinical and blood parameters.基于临床和血液参数的非酒精性脂肪性肝炎早期检测的机器学习方法。
Sci Rep. 2024 Jan 30;14(1):2442. doi: 10.1038/s41598-024-51741-0.
9
Predicting misdiagnosed adult-onset type 1 diabetes using machine learning.使用机器学习预测误诊的成人发病 1 型糖尿病。
Diabetes Res Clin Pract. 2022 Sep;191:110029. doi: 10.1016/j.diabres.2022.110029. Epub 2022 Aug 5.
非酒精性脂肪肝和肝纤维化预测分析:用于改善预防医学的风险预测和机器学习技术。
J Med Syst. 2021 Jan 11;45(2):22. doi: 10.1007/s10916-020-01693-5.
4
Finding undiagnosed patients with hepatitis C infection: an application of artificial intelligence to patient claims data.发现未确诊的丙型肝炎感染患者:人工智能在患者索赔数据中的应用。
Sci Rep. 2020 Jun 29;10(1):10521. doi: 10.1038/s41598-020-67013-6.
5
Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts.预测和阐明脂肪肝疾病的病因:在 IMI DIRECT 队列中进行机器学习建模和验证研究。
PLoS Med. 2020 Jun 19;17(6):e1003149. doi: 10.1371/journal.pmed.1003149. eCollection 2020 Jun.
6
Development of an Algorithm to Identify Cases of Nonalcoholic Steatohepatitis Cirrhosis in the Electronic Health Record.开发一种在电子健康记录中识别非酒精性脂肪性肝炎肝硬化病例的算法。
Dig Dis Sci. 2021 May;66(5):1452-1460. doi: 10.1007/s10620-020-06388-y. Epub 2020 Jun 13.
7
Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.非酒精性脂肪性肝病向肝硬化的进展率及肝硬化向失代偿和死亡率的进展:医疗保险数据的真实世界分析。
Aliment Pharmacol Ther. 2020 Jun;51(11):1149-1159. doi: 10.1111/apt.15679. Epub 2020 May 5.
8
Predicting hospital readmission in patients with mental or substance use disorders: A machine learning approach.预测精神或物质使用障碍患者的住院再入院:一种机器学习方法。
Int J Med Inform. 2020 Jul;139:104136. doi: 10.1016/j.ijmedinf.2020.104136. Epub 2020 Apr 18.
9
Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.基于组学和有监督学习的非酒精性脂肪性肝炎和肝纤维化的无创诊断:概念验证研究。
Metabolism. 2019 Dec;101:154005. doi: 10.1016/j.metabol.2019.154005. Epub 2019 Nov 9.
10
Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).非酒精性脂肪性肝病 (NAFLD) 和非酒精性脂肪性肝炎 (NASH) 的检测现状。
Cells. 2019 Aug 7;8(8):845. doi: 10.3390/cells8080845.